DFS tended to be shorter in DCIS-Mi patients who were HER2 positive than in those who were HER2 negative [Supplementary Figure S4D: (Fixed-effects model) HR, 5.79; 95% CI, 0.99–33.90; p = 0.05, (Random-effects model) HR, 5.99; 95% CI, 0.52–69.75; p = 0.15], but the difference was not significant. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.